Introduction
The US Food and Drug Administration (FDA) approved Symbyax (olanzapine and fluoxetine HCl) for use as a combination product in the treatment of depressive episodes associated with bipolar disorder. Also approved by the FDA was the use of Zyprexa (olanzapine) in the long-term treatment of bipolar I disorder.
Eloxatin (oxaliplatin) injection in combination with infusional 5-fluorouracil (5-FU) and leucovorin (LV) was approved for the treatment of patients previously untreated for advanced colorectal cancer.
This month's column reviews FDA new product approvals and labeling changes for:
Antidepressants
|
Anti-infective Agents
|
Antineoplastic Agents
|
Antipsychotic Agents
|
Cardiovascular Agents
|
Medscape Pharmacists. 2004;5(1) © 2004 Medscape
Cite this: February 2004 - Medscape - Feb 13, 2004.
